image dons

je fais un don

Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial

Bourses ACTION & PHRA 2023
Plus que quelques jours pour soumettre vos projets !!!

La Grande Journée du Coeur (mardi 13 juin 2023)
Réservez vos places pour la 5e édition !

21e Colloquium de l'Institut - Le risque cardiaque et vasculaire (14 mars 2023)
Présentations bientôt en ligne !

American Heart Journal 2021 Feb;232:185-193
Article disponible en consultant le site


Braik N, Guedeney P, Behnes M, Desch S, Barthélémy O, Sandri M, de Waha-Thiele S, Fuernau G, Rouanet S, Hauguel-Moreau M, Zeitouni M, Overtchouk P, Ouarrak T, Schneider S, Zeymer U, Thiele H, Montalescot G, Akin I.



The impact of coronary artery chronic total occlusion (CTO) and its management with percutaneous coronary intervention (PCI) in the setting of myocardial infarction (MI) related cardiogenic shock (CS) remains unclear.


This is a pre-specified analysis from the culprit-lesion-only PCI vs multivessel PCI in CS (CULPRIT-SHOCK) trial which randomized patients presenting with MI and multivessel disease complicated by CS to a culprit-lesion-only or immediate multivessel PCI strategy.


CTO was defined by central core-laboratory evaluation. The independent associations between the presence of CTO and adverse outcomes at 30 days and 1 year were assessed using multivariate logistics models.


A noninfarct related CTO was present in 157 of 667 (23.5%) analyzed patients. Patients presenting with CTO had more frequent diabetes mellitus or prior PCI but less frequently presented with ST segment elevation MI as index event. The presence of CTO was associated with higher rate of death at 30 days (adjusted Odds ratio 1.63; 95% confidence interval [CI] 1.01-2.60). Rate of death at 1 year was also increased but did not reach statistical significance (adjusted Odds ratio 1.62; 95%CI 0.99-2.66). Compare to immediate multivessel PCI, a strategy of culprit-lesion-only PCI was associated with lower rates of death or renal replacement therapy at 30 days in patients with and without CTO (Odds ratio 0.79 95%CI 0.42-1.49 and Odds ratio 0.67 95%CI 0.48-0.96, respectively), without significant interaction (P = .68).


In patients with MI-related CS and multivessel disease, the presence of CTO is associated with adverse outcomes while a strategy of culprit-lesion-only PCI seems beneficial regardless of the presence of CTO.

Autres actualités



Bleeding in the Elderly: Risk Factors and Impact on Clinical...

Am J Cardiovasc Drugs. 2021 Nov;21(6):681-691


Pretreatment in the Setting of Non-ST-Elevated Acute Coronar...

JAMA Netw Open. 2021 Nov 1;4(11):e2134472


RAS inhibition and COVID-19: more questions than answers ?

Lancet Respir Med. 2021 Aug;9(8):807-809